Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 238

1.

Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).

Dennehy PH, Vesikari T, Matson DO, Itzler RF, Dallas MJ, Goveia MG, DiNubile MJ, Heaton PM, Ciarlet M.

Hum Vaccin. 2011 May;7(5):563-8. Epub 2011 May 1.

PMID:
21441783
2.

Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States.

Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD.

Pediatr Infect Dis J. 2013 Mar;32(3):278-83. doi: 10.1097/INF.0b013e318275328f.

PMID:
23014356
3.

Efficacy of the oral pentavalent rotavirus vaccine in Mali.

Sow SO, Tapia M, Haidara FC, Ciarlet M, Diallo F, Kodio M, Doumbia M, Dembélé RD, Traoré O, Onwuchekwa UU, Lewis KD, Victor JC, Steele AD, Neuzil KM, Kotloff KL, Levine MM.

Vaccine. 2012 Apr 27;30 Suppl 1:A71-8. doi: 10.1016/j.vaccine.2011.11.094.

PMID:
22520140
4.

Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa.

Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis KD, Sow SO, Rivers SB, Levine MM, Laserson KF, Feikin DR, Victor JC, Ciarlet M, Neuzil KM, Steele AD.

Vaccine. 2012 Apr 27;30 Suppl 1:A79-85. doi: 10.1016/j.vaccine.2012.01.022.

PMID:
22520141
5.

Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine.

Breiman RF, Zaman K, Armah G, Sow SO, Anh DD, Victor JC, Hille D, Ciarlet M, Neuzil KM.

Vaccine. 2012 Apr 27;30 Suppl 1:A24-9. doi: 10.1016/j.vaccine.2011.08.124.

PMID:
22520132
6.

RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.

Vesikari T, Itzler R, Karvonen A, Korhonen T, Van Damme P, Behre U, Bona G, Gothefors L, Heaton PM, Dallas M, Goveia MG.

Vaccine. 2009 Dec 11;28(2):345-51. doi: 10.1016/j.vaccine.2009.10.041. Epub 2009 Oct 29.

PMID:
19879226
7.

Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial.

Iwata S, Nakata S, Ukae S, Koizumi Y, Morita Y, Kuroki H, Tanaka Y, Shizuya T, Schödel F, Brown ML, Lawrence J.

Hum Vaccin Immunother. 2013 Aug;9(8):1626-33. doi: 10.4161/hv.24846. Epub 2013 May 31.

8.

Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5).

Itzler R, Koch G, Matson DO, Gothefors L, Van Damme P, Dinubile MJ, Heaton PM.

BMC Pediatr. 2010 Jun 11;10:42. doi: 10.1186/1471-2431-10-42.

9.

Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.

Feikin DR, Laserson KF, Ojwando J, Nyambane G, Ssempijja V, Audi A, Nyakundi D, Oyieko J, Dallas MJ, Ciarlet M, Neuzil KM, Breiman RF.

Vaccine. 2012 Apr 27;30 Suppl 1:A52-60. doi: 10.1016/j.vaccine.2011.08.043.

PMID:
22520137
10.

Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study.

Vesikari T, Karvonen A, Ferrante SA, Ciarlet M.

Eur J Pediatr. 2010 Nov;169(11):1379-86. doi: 10.1007/s00431-010-1242-3. Epub 2010 Jun 18.

11.

Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine.

Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M.

Pediatr Infect Dis J. 2010 Oct;29(10):957-63. doi: 10.1097/INF.0b013e3181e28e6e.

PMID:
20442684
12.

Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.

Laserson KF, Nyakundi D, Feikin DR, Nyambane G, Cook E, Oyieko J, Ojwando J, Rivers SB, Ciarlet M, Neuzil KM, Breiman RF.

Vaccine. 2012 Apr 27;30 Suppl 1:A61-70. doi: 10.1016/j.vaccine.2011.09.026.

PMID:
22520138
13.

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM; Rotavirus Efficacy and Safety Trial (REST) Study Team.

N Engl J Med. 2006 Jan 5;354(1):23-33.

14.

Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States.

Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD.

Pediatrics. 2010 Feb;125(2):e208-13. doi: 10.1542/peds.2009-1246. Epub 2010 Jan 25.

PMID:
20100757
15.

Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.

Ciarlet M, Schödel F.

Vaccine. 2009 Dec 30;27 Suppl 6:G72-81. doi: 10.1016/j.vaccine.2009.09.107. Review.

PMID:
20006144
16.

Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States.

Boom JA, Tate JE, Sahni LC, Rench MA, Hull JJ, Gentsch JR, Patel MM, Baker CJ, Parashar UD.

Pediatrics. 2010 Feb;125(2):e199-207. doi: 10.1542/peds.2009-1021. Epub 2010 Jan 18.

PMID:
20083525
17.

Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial.

Madhi SA, Kirsten M, Louw C, Bos P, Aspinall S, Bouckenooghe A, Neuzil KM, Steele AD.

Vaccine. 2012 Apr 27;30 Suppl 1:A44-51. doi: 10.1016/j.vaccine.2011.08.080.

PMID:
22520136
18.

Rotavirus live, oral, pentavalent vaccine.

Tom-Revzon C.

Clin Ther. 2007 Dec;29(12):2724-37. doi: 10.1016/j.clinthera.2007.12.018. Review.

PMID:
18201590
19.

Immunogenicity of the pentavalent rotavirus vaccine in African infants.

Armah GE, Breiman RF, Tapia MD, Dallas MJ, Neuzil KM, Binka FN, Sow SO, Ojwando J, Ciarlet M, Steele AD.

Vaccine. 2012 Apr 27;30 Suppl 1:A86-93. doi: 10.1016/j.vaccine.2011.10.006.

PMID:
22520142
20.

Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses.

Goveia MG, Suprun L, Itzler RF, McFetridge R, Dallas MJ, Kuter BJ.

Pediatr Infect Dis J. 2010 Mar;29(3):263-5. doi: 10.1097/INF.0b013e3181be6257.

PMID:
19949360

Supplemental Content

Support Center